SI3150199T1 - Novi sestavek alfentanila za zdravljenje akutne bolečine - Google Patents

Novi sestavek alfentanila za zdravljenje akutne bolečine

Info

Publication number
SI3150199T1
SI3150199T1 SI201331238T SI201331238T SI3150199T1 SI 3150199 T1 SI3150199 T1 SI 3150199T1 SI 201331238 T SI201331238 T SI 201331238T SI 201331238 T SI201331238 T SI 201331238T SI 3150199 T1 SI3150199 T1 SI 3150199T1
Authority
SI
Slovenia
Prior art keywords
treatment
new
acute pain
alfentanil
composition
Prior art date
Application number
SI201331238T
Other languages
English (en)
Slovenian (sl)
Inventor
Anders Pettersson
Emil Schwan
Barbro Johansson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3150199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of SI3150199T1 publication Critical patent/SI3150199T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201331238T 2012-05-02 2013-05-01 Novi sestavek alfentanila za zdravljenje akutne bolečine SI3150199T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition
EP16197166.8A EP3150199B1 (en) 2012-05-02 2013-05-01 New alfentanil composition for the treatment of acute pain

Publications (1)

Publication Number Publication Date
SI3150199T1 true SI3150199T1 (sl) 2018-12-31

Family

ID=48577134

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201330490A SI2849730T1 (sl) 2012-05-02 2013-05-01 Novi sestavek alfentanila za zdravljenje akutne bolečine
SI201331238T SI3150199T1 (sl) 2012-05-02 2013-05-01 Novi sestavek alfentanila za zdravljenje akutne bolečine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201330490A SI2849730T1 (sl) 2012-05-02 2013-05-01 Novi sestavek alfentanila za zdravljenje akutne bolečine

Country Status (33)

Country Link
US (4) US8815911B2 (OSRAM)
EP (2) EP3150199B1 (OSRAM)
JP (1) JP6275696B2 (OSRAM)
KR (1) KR20150005695A (OSRAM)
CN (1) CN104427978B (OSRAM)
AU (1) AU2013255640B2 (OSRAM)
BR (1) BR112014027213A8 (OSRAM)
CA (1) CA2871805A1 (OSRAM)
CL (1) CL2014002979A1 (OSRAM)
CO (1) CO7170181A2 (OSRAM)
CY (2) CY1118570T1 (OSRAM)
DK (2) DK2849730T3 (OSRAM)
EA (1) EA028110B1 (OSRAM)
ES (2) ES2694644T3 (OSRAM)
HR (2) HRP20161634T1 (OSRAM)
HU (1) HUE031792T2 (OSRAM)
IL (1) IL235272B (OSRAM)
IN (1) IN2014MN02156A (OSRAM)
LT (2) LT3150199T (OSRAM)
ME (1) ME02644B (OSRAM)
MX (1) MX360665B (OSRAM)
NZ (1) NZ701428A (OSRAM)
PE (1) PE20142444A1 (OSRAM)
PH (1) PH12014502407B1 (OSRAM)
PL (2) PL2849730T3 (OSRAM)
PT (2) PT2849730T (OSRAM)
RS (2) RS55489B1 (OSRAM)
SG (1) SG11201407081PA (OSRAM)
SI (2) SI2849730T1 (OSRAM)
SM (3) SMT201700086T1 (OSRAM)
TR (1) TR201815935T4 (OSRAM)
WO (1) WO2013164620A1 (OSRAM)
ZA (1) ZA201407559B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
BR112014027213A8 (pt) * 2012-05-02 2018-01-16 Orexo Ab nova composição de alfentanil para o tratamento de dor aguda
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109B (zh) * 2022-06-17 2024-05-31 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2004067004A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
EP2316418A3 (en) 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
ME01300B (me) 2003-12-31 2013-12-20 Cima Labs Inc Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja
AU2004311879B2 (en) 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20080248110A1 (en) 2005-03-28 2008-10-09 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
DK2054031T3 (en) * 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
JP5484062B2 (ja) 2006-12-04 2014-05-07 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
WO2009021106A1 (en) 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
WO2010027770A1 (en) 2008-09-04 2010-03-11 Mallinckrodt Inc. Crystalline forms of sufentanil citrate
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
JP2012526840A (ja) 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
BR112014027213A8 (pt) * 2012-05-02 2018-01-16 Orexo Ab nova composição de alfentanil para o tratamento de dor aguda

Also Published As

Publication number Publication date
EP3150199B1 (en) 2018-08-08
EP2849730B1 (en) 2016-11-09
US8815911B2 (en) 2014-08-26
KR20150005695A (ko) 2015-01-14
LT3150199T (lt) 2018-11-12
AU2013255640A1 (en) 2014-11-20
LT2849730T (lt) 2016-12-27
ES2614757T3 (es) 2017-06-01
ME02644B (me) 2017-06-20
CN104427978A (zh) 2015-03-18
CO7170181A2 (es) 2015-01-28
TR201815935T4 (tr) 2018-11-21
US20180214437A1 (en) 2018-08-02
EP2849730A1 (en) 2015-03-25
US20170071927A1 (en) 2017-03-16
CY1118570T1 (el) 2017-07-12
JP6275696B2 (ja) 2018-02-14
NZ701428A (en) 2016-10-28
BR112014027213A8 (pt) 2018-01-16
SG11201407081PA (en) 2014-11-27
RS57951B1 (sr) 2019-01-31
CL2014002979A1 (es) 2014-12-05
SMT201700086T1 (it) 2017-03-08
HRP20181761T1 (hr) 2018-12-28
PH12014502407A1 (en) 2015-01-12
MX2014013176A (es) 2015-01-19
ZA201407559B (en) 2016-05-25
DK2849730T3 (en) 2017-02-13
EA201401200A1 (ru) 2015-02-27
HRP20161634T1 (hr) 2017-01-13
CA2871805A1 (en) 2013-11-07
HUE031792T2 (en) 2017-07-28
IN2014MN02156A (OSRAM) 2015-08-28
PL3150199T3 (pl) 2019-03-29
US20140005223A1 (en) 2014-01-02
PE20142444A1 (es) 2015-01-09
IL235272B (en) 2018-10-31
EA028110B1 (ru) 2017-10-31
DK3150199T3 (en) 2018-11-12
BR112014027213A2 (pt) 2017-06-27
US20150133501A1 (en) 2015-05-14
ES2694644T3 (es) 2018-12-26
PH12014502407B1 (en) 2015-01-12
SI2849730T1 (sl) 2017-02-28
PT3150199T (pt) 2018-11-21
WO2013164620A1 (en) 2013-11-07
HK1203399A1 (en) 2015-10-30
US9782396B2 (en) 2017-10-10
CN104427978B (zh) 2017-03-01
PL2849730T3 (pl) 2017-05-31
JP2015515974A (ja) 2015-06-04
RS55489B1 (sr) 2017-04-28
SMT201800585T1 (it) 2019-01-11
US9345698B2 (en) 2016-05-24
SMT201700086B (it) 2017-03-08
EP3150199A1 (en) 2017-04-05
CY1120820T1 (el) 2019-12-11
AU2013255640B2 (en) 2017-06-15
MX360665B (es) 2018-11-13
PT2849730T (pt) 2017-02-15

Similar Documents

Publication Publication Date Title
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
ZA201408055B (en) Compositions and methods for the treatment of local pain
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
SMT201800604T1 (it) Composti per il trattamento di obesita' e metodi di uso degli stessi
ZA201405161B (en) Hair treatment composition
ZA201305939B (en) Hair treatment composition
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
IL234616A0 (en) A herbal preparation for the treatment of metabolic diseases
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
HUE039044T2 (hu) Gyógyászati kompozíció sclerosis multiplex kezelésére
ZA201501109B (en) Hard surface treatment composition
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201110659D0 (en) composition for skin treatment
GB201110653D0 (en) Composition for skin treatment